Nosocomial pneumonia: De-escalation is what matters

The Lancet Infectious Diseases

Volumn 11, Issue 3, 2011, Pages 155-157

  Ewig, Santiago ^a  

^a Augusta Kranken Anstalt   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COLISTIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; LETTER; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79952040614     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70003-2     Document Type: Letter

References (12)

1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society, Infectious Diseases Society of AmericaInfectious Diseases Society of America.
2. Kett DH, Cano E, Quartin AA, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, the Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators, published online Jan 20. 10.1016/S1473-3099(10)70314-5.
3. Barrantes F, Tian J, Vazquez R, Amoateng-Adjepong Y, Manthous CA Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med 2008, 36:1397-1403.
4. Chamot E, Boffi El, Amari E, Rohner P, Van Delden C Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003, 47:2756-2764.
5. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35:1888-1895.
6. Martínez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a β-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010, 54:3590-3596.
7. Safdar N, Handelsman J, Maki DG Does combination antimicrobial therapy reduced mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527.
8. Heyland DK, Dodek P, Muscedere J, Day A, Cook D Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744. Canadian Critical Care Trials Group.
9. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008, 36:108-117.
10. Al-Hasan MN, Wilson JW, Lahr BD, et al. β-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli. Antimicrob Agents Chemother 2009, 53:1386-1394.
11. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005, 41:149-581.
12. Ewig S, Welte T, Chastre J, Torres A Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010, 10:279-287.